GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sino Biopharmaceutical 1177.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

5.47

-2.32%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥37.12bn

FY2016FY2025

Net income

CN¥2.73bn

FY2016FY2025

Free cash flow

CN¥8.85bn

FY2016FY2025

Shareholders' equity

CN¥35.78bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥37.12bnCN¥28.87bnCN¥30.55bnCN¥26.03bnCN¥31.32bnCN¥27.57bnCN¥28.26bnCN¥24.36bnCN¥17.28bnCN¥16.52bn
Gross profitCN¥30.47bnCN¥23.53bnCN¥24.73bnCN¥21.54bnCN¥25.11bnCN¥21.53bnCN¥22.51bnCN¥19.46bnCN¥13.68bnCN¥13.09bn
Research and developmentCN¥7.04bnCN¥5.23bnCN¥5.22bnCN¥4.33bnCN¥4.37bnCN¥3.06bnCN¥2.80bnCN¥2.44bnCN¥1.86bnCN¥1.60bn
Operating incomeCN¥8.11bnCN¥6.14bnCN¥6.75bnCN¥5.59bnCN¥5.92bnCN¥4.78bnCN¥6.77bnCN¥5.80bnCN¥4.87bnCN¥5.50bn
Net incomeCN¥2.73bnCN¥3.50bnCN¥2.72bnCN¥2.54bnCN¥17.03bnCN¥3.23bnCN¥5.47bnCN¥10.55bnCN¥2.53bnCN¥2.00bn
Diluted earnings per share0.150.190.140.130.880.170.290.570.180.12

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥88.67bnCN¥76.27bnCN¥74.17bnCN¥74.71bnCN¥70.60bnCN¥55.05bnCN¥67.98bnCN¥58.05bnCN¥24.41bnCN¥21.45bn
Cash and short-term investmentsCN¥26.78bnCN¥17.02bnCN¥16.46bnCN¥19.73bnCN¥18.42bnCN¥18.05bnCN¥22.28bnCN¥15.19bnCN¥11.55bnCN¥10.00bn
Total liabilitiesCN¥38.85bnCN¥26.39bnCN¥29.66bnCN¥30.46bnCN¥26.60bnCN¥28.91bnCN¥21.01bnCN¥14.26bnCN¥9.71bnCN¥8.98bn
DebtCN¥18.77bnCN¥9.72bnCN¥12.72bnCN¥14.12bnCN¥12.41bnCN¥14.65bnCN¥8.62bnCN¥3.41bnCN¥2.95bnCN¥3.05bn
Shareholders' equityCN¥35.78bnCN¥37.27bnCN¥35.54bnCN¥34.69bnCN¥35.32bnCN¥19.53bnCN¥36.28bnCN¥34.07bnCN¥10.74bnCN¥9.22bn
Shares outstanding18,001m18,180m18,801m18,912m19,277m18,862m18,873m18,358m14,398m16,677m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥10.84bnCN¥6.62bnCN¥7.07bnCN¥7.31bnCN¥6.26bnCN¥6.21bnCN¥6.21bnCN¥5.94bnCN¥4.35bnCN¥3.60bn
Capital spending−CN¥1.99bn−CN¥1.39bn−CN¥1.99bn−CN¥1.99bn−CN¥2.21bn−CN¥2.17bn−CN¥2.02bn−CN¥1.97bn−CN¥1.70bn−CN¥1.09bn
Free cash flowCN¥8.85bnCN¥5.22bnCN¥5.09bnCN¥5.32bnCN¥4.05bnCN¥4.04bnCN¥4.19bnCN¥3.97bnCN¥2.65bnCN¥2.51bn
Dividends paid−CN¥1.75bn−CN¥1.85bn−CN¥737.8m−CN¥1.48bn−CN¥1.09bn−CN¥1.38bn−CN¥955.8m−CN¥828.3m−CN¥524.7m−CN¥464.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥11.34bnCN¥11.34bnCN¥8.31bnCN¥8.31bnCN¥10.25bnCN¥10.25bnCN¥6.50bnCN¥7.57bn
Gross profitCN¥9.41bnCN¥9.41bnCN¥6.78bnCN¥6.78bnCN¥8.45bnCN¥8.45bnCN¥5.25bnCN¥6.12bn
Operating incomeCN¥3.99bnCN¥3.99bnCN¥1.86bnCN¥1.86bnCN¥2.19bnCN¥2.19bnCN¥1.19bnCN¥1.39bn
Net incomeCN¥2.00bnCN¥2.00bn−CN¥609.4m−CN¥609.4mCN¥1.98bnCN¥1.98bnCN¥241.3mCN¥281.4m
Diluted earnings per share0.110.11-0.03-0.030.110.110.010.02
Cash from operations——CN¥3.57bnCN¥3.57bnCN¥1.84bnCN¥1.84bnCN¥7.71bn—
Capital spending——−CN¥564.0m−CN¥564.0m−CN¥157.0m−CN¥157.0m−CN¥1.12bn—
Free cash flow——CN¥3.01bnCN¥3.01bnCN¥1.69bnCN¥1.69bnCN¥6.59bn—
Total assetsCN¥97.03bnCN¥97.03bnCN¥88.63bnCN¥88.63bnCN¥87.33bnCN¥87.33bnCN¥65.41bnCN¥76.27bn
Cash and short-term investmentsCN¥32.16bnCN¥32.16bnCN¥26.30bnCN¥26.78bnCN¥23.12bnCN¥23.12bnCN¥14.60bnCN¥17.02bn
DebtCN¥10.12bnCN¥10.12bnCN¥18.74bnCN¥9.82bnCN¥13.94bnCN¥10.35bnCN¥9.78bnCN¥8.98bn
Shareholders' equityCN¥37.98bnCN¥37.98bnCN¥35.77bnCN¥35.77bnCN¥38.92bnCN¥38.92bnCN¥31.96bnCN¥37.27bn

Financial ratios

Data as of 9 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin82.1%81.5%81.0%82.8%80.1%78.1%
Operating margin21.8%21.3%22.1%21.5%18.9%17.3%
Net margin7.4%12.1%8.9%9.8%54.4%11.7%
Return on equity7.6%11.0%7.7%8.6%48.2%16.5%
Return on assets3.1%5.4%3.7%4.0%24.1%5.9%
Free cash flow yield10.9%7.9%7.4%7.5%6.7%6.8%
Revenue growth10.3%10.2%0.7%-3.1%13.6%-2.4%
Earnings growth-33.0%50.1%-8.3%-82.6%427.2%-41.0%
Current ratio1.37x1.26x1.05x1.29x1.53x2.08x
Debt to equity0.52x0.30x0.40x0.46x0.39x0.86x
Equity ratio40.4%48.9%47.9%46.4%50.0%35.5%
Interest coverage25.65x20.79x11.68x13.01x16.46x12.67x
R&D as a share of sales19.0%18.1%17.1%16.6%13.9%11.1%
Buybacks as a share of market value1.0%3.3%0.6%1.9%-2.2%0.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.6%6.1%10.1%
Operating income13.2%11.2%10.0%
Net income2.4%-3.3%4.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin81.8%81.8%81.0%80.4%
Operating margin21.6%21.7%20.5%22.5%
Net margin9.4%9.4%17.5%19.2%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings35.814.621.129.95.438.522.05.330.817.8
Price to sales2.61.81.92.93.04.54.32.34.52.1

Dividends and splits

Per share, in the currency the company pays

Paid for 25 years. Last went ex-dividend on 24 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.050.090.060.080.100.040.0530.04
  • 3-for-2 split · 20 Jul 2020
  • 3-for-2 split · 4 Jun 2018
  • 3-for-2 split · 13 Nov 2015
  • 3-for-2 split · 4 Dec 2009
  • 4-for-3 split · 3 Jun 2009
  • 3-for-2 split · 6 May 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.